This is Ingrid A. Pelzer's Typepad Profile.
Join Typepad and start following Ingrid A. Pelzer's activity
Join Now!
Already a member? Sign In
Ingrid A. Pelzer
Recent Activity
Image
By James Brenner and Richard Velardi On January 6, 2015, the U.S. House of Representatives introduced House Bill 160 (H.R. 160), also known as the Protect Medical Innovation Act. As introduced, H.R. 160 would repeal the 2.3% medical device excise tax, which was enacted in 2010 as part of the... Continue reading
Posted Jan 15, 2015 at Pharmaspective
Image
By Rena Bartel and Ingrid Pelzer On July 27, 2012, the Alameda County Board of Supervisors, located in Northern California, passed the Safe Drug Disposal Ordinance (Ordinance). The Ordinance, which was scheduled to go into effect on November 1, 2013, requires Producers to fund or operate “take-back” programs in Alameda... Continue reading
Posted Jan 14, 2015 at Pharmaspective
Image
By Ingrid Pelzer and Rakan Ghubej The Connecticut State Legislature was busy in 2014! Due to legislative updates, qualified advanced practice registered nurses ("APRNs") in Connecticut are permitted to practice and prescribe medication without having a collaborative relationship with a licensed physician. Previously, APRNs were required to practice, prescribe, dispense,... Continue reading
Posted Jan 8, 2015 at Pharmaspective
Image
By Ingrid A. Pelzer According to the Drug Supply Chain Security Act ("DSCSA"), effective January 1, 2015, manufacturers and wholesale distributors that transfer ownership of a product will be required to provide the subsequent owner with transaction history, transaction information, and a transaction statement in a single document in paper... Continue reading
Posted Dec 29, 2014 at Pharmaspective
Image
By Kerry M. Miele On June 20, 2013, the Board of Health (Board) in King County, Washington passed the Secure Medicine Return Regulations (Regulations), establishing a program to collect and properly dispose of unwanted medicines from local residents. According to the Regulations, the program will be funded and operated by... Continue reading
Posted Nov 11, 2014 at Pharmaspective
Image
By Ingrid A. Pelzer, Laura C. Conway, and Christine Bradshaw In July 2014, the Centers for Medicare and Medicaid Services (CMS) published proposed amendments to its rules implementing the Sunshine Act. Among other things, CMS proposed to remove section 403.904(g)(1), which previously stated that applicable manufacturers were not required to... Continue reading
Posted Nov 6, 2014 at Pharmaspective
Image
By Ingrid A. Pelzer and Christine N. Bradshaw The Centers for Medicare and Medicaid Services (CMS) has released the first round of Sunshine Act data on its freshly-updated Open Payments website. The Sunshine Act requires applicable manufacturers of covered drugs, devices, biological products, and medical supplies to report annually certain... Continue reading
Posted Oct 2, 2014 at Pharmaspective
Image
By Rachael Garrison and Ingrid Pelzer In November 2013, several members of Congress submitted a letter to Marilyn Tavenner, Administrator of the Centers for Medicare and Medicaid Services (CMS), urging that the distribution of textbooks and scientific peer-reviewed medical journal materials be excluded from the reporting requirements under the Sunshine... Continue reading
Posted Sep 29, 2014 at Pharmaspective
Image
By Ingrid A. Pelzer On Friday, August 15, 2014, the Centers for Medicare and Medicaid Services (CMS) announced that it had reopened the Open Payments system for physicians, teaching hospitals, and authorized representatives to register and review data. CMS had previously taken the system offline to investigate a report of... Continue reading
Posted Aug 18, 2014 at Pharmaspective
Image
By Rena Bartel On Thursday, August 7, 2014, the Centers for Medicare & Medicaid Services (CMS) announced that the Open Payments system was taken offline temporarily in order to investigate an issue. Reportedly, a physician complained to CMS when, upon logging into the CMS Open Payments portal to view the... Continue reading
Posted Aug 11, 2014 at Pharmaspective
Image
By Rena Bartel and Ingrid Pelzer On November 27, 2013, President Obama signed into law the "Drug Quality and Security Act," which amends the Federal Food, Drug, and Cosmetic Act. Title II of the Act, also known as the "Drug Supply Chain Security Act” (DSCSA), establishes a timeline for entities... Continue reading
Posted Aug 4, 2014 at Pharmaspective
Image
By Danielle Burke In addition to imposing payment and physician ownership disclosure requirements, the federal Patient Protection and Affordable Care Act (Act) also requires manufacturers and authorized distributors of record (ADRs) to disclose information related to drug sample requests and distributions. Specifically, the Act states that beginning April 1, 2012,... Continue reading
Posted Jul 21, 2014 at Pharmaspective
Image
By Ingrid A. Pelzer According to the Sunshine Act and its implementing regulations, applicable manufacturers, applicable group purchasing organizations (GPOs), covered recipients, and physician owners or investors must have an opportunity to review and submit corrections to the data submitted pursuant to the Sunshine Act. This review and correction period... Continue reading
Posted Jul 14, 2014 at Pharmaspective
Image
By Ingrid A. Pelzer and Kiaema R. Reid On July 3, 2014, the Centers for Medicare and Medicaid Services (CMS) published proposed amendments to its rules implementing the Sunshine Act. Among other things, the proposed amendments would remove section 403.904(g)(1), which currently excludes the reporting of payments associated with certain... Continue reading
Posted Jul 8, 2014 at Pharmaspective
Image
By Grant Ostlund and Nicole Morris On July 2, 2014, the federal Drug Enforcement Administration (DEA) published a Final Rule in the Federal Register to place Tramadol into Schedule IV of the Controlled Substances Act (CSA). The DEA began its consideration to schedule Tramadol after a recommendation from the Assistant... Continue reading
Posted Jul 3, 2014 at Pharmaspective
Image
By Ingrid Pelzer (@IngridPelzer) As previously reported, the Centers for Medicare and Medicaid Services (CMS) has adopted a two-phased approach for registration and submission of Sunshine Act data for the 2013 reporting year. Phase 1 began on February 18, 2014, and concluded on March 31, 2014. Phase 2 began on... Continue reading
Posted Jul 1, 2014 at Pharmaspective
Image
By Ingrid A. Pelzer (@IngridPelzer) The Centers for Medicare and Medicaid Services (CMS) has announced that Open Payments registration and detailed data submission for applicable manufacturers and group purchasing organizations (GPOs) will begin on June 1, 2014, and will be completed in two steps. CMS has released an instructions document... Continue reading
Posted May 27, 2014 at Pharmaspective
Image
By Ingrid A. Pelzer (@IngridPelzer) The District of Columbia's (D.C.) Prescription Drug Marketing Cost Reporting Law (D.C. CODE § 48-833.01-09) requires manufacturers and labelers of prescription drugs dispensed in D.C. that employ, direct, or utilize marketing representatives in D.C. to submit an annual report disclosing certain prescription drug marketing costs.... Continue reading
Posted May 21, 2014 at Pharmaspective
Image
By Kim C. Capone In a notice published in the Federal Register on May 7, 2014, the federal Food and Drug Administration (FDA) is soliciting comments on a proposed study entitled "Comparative Price Information in Direct-to-Consumer and Professional Prescription Drug Advertisements." The FDA's Office of Prescription Drug Promotion (OPDP) will... Continue reading
Posted May 20, 2014 at Pharmaspective
Image
By Christina Codispoti On May 8, 2014, the Governor of Connecticut signed Senate Bill 36 (SB 36), which will amend the Connecticut Nursing Practice Act. Effective July 1, 2014, SB 36 will permit qualified advanced practice registered nurses (APRNs) to practice and prescribe medication without having a collaborative relationship with... Continue reading
Posted May 19, 2014 at Pharmaspective
By Ingrid A. Pelzer (@IngridPelzerPLS) As previously reported, the Centers for Medicare and Medicaid Services (CMS) has adopted a two-phased approach for registration and submission of Sunshine Act* data for the 2013 reporting year. Phase 1 of CMS' Open Payments registration and data submission for applicable manufacturers and applicable group... Continue reading
Posted May 9, 2014 at Pharmaspective
Image
By Ingrid A. Pelzer (@IngridPelzerPLS) The Centers for Medicare and Medicaid Services (CMS) has made updates to its data submission resources, which applicable manufacturers and applicable group purchasing organizations (GPOs) will use to submit data during Phase 2 of Open Payments registration and data submission. During Phase 2, which is... Continue reading
Posted May 8, 2014 at Pharmaspective
By Rakan Ghubej In July 2013, the Centers for Medicare and Medicaid Services (CMS) submitted an information collection request (ICR) to the Office of Management and Budget (OMB), and invited interested parties to submit comments regarding implementation of the Sunshine Act. Among other things, interested parties were asked to comment... Continue reading
Posted May 7, 2014 at Pharmaspective
Image
By Ingrid A. Pelzer (@IngridPelzerPLS) On February 1, 2013, the Centers for Medicare and Medicaid Services (CMS) announced the release of the final regulations implementing the Transparency Reports and Reporting of Physician Ownership or Investment Interests section of the Patient Protection and Affordable Care Act, commonly referred to as the... Continue reading
Posted May 5, 2014 at Pharmaspective
Image
By Ingrid A. Pelzer (@IngridPelzerPLS) As previously reported, the Centers for Medicare and Medicaid Services (CMS) has adopted a two-phased approach for registration and submission of Sunshine Act data for the 2013 reporting year. Phase 1 of CMS' Open Payments registration and data submission process for applicable manufacturers and applicable... Continue reading
Posted May 2, 2014 at Pharmaspective